tbuckley/cabot-search huggingface dataset:
Histopathology of Veins Obtained at Hemodialysis Arteriovenous Fistula Creation Surgery
Authors: Charles E. Alpers, Peter B. Imrey, Kelly L. Hudkins, Tomasz A. Wietecha, Milena Radeva, Michael Allon, Alfred K. Cheung, Laura M. Dember, Prabir Roy-Chaudhury, Yan-Ting Shiu, Christi M. Terry, Alik Farber, Gerald J. Beck, Harold I. Feldman, John W. Kusek, Jonathan Himmelfarb
Journal: Journal of the American Society of Nephrology (2017)

Stenosis from venous neointimal hyperplasia is common in native arteriovenous fistulas (AVFs). However, the preexisting histologic characteristics of veins at fistula creation, and associations thereof with baseline patient factors, have not been well characterized. In this study, we conducted histologic analysis of a segment of the vein used for anastomosis creation, obtained during AVF creation from 554 of the 602 participants in the multicenter Hemodialysis Fistula Maturation Cohort Study. We quantified intimal and medial areas and lengths of the internal and external elastic lamina by morphometry and assessed venous wall cells by immunohistochemistry, extracellular matrix with Movat stain, and calcium deposition by alizarin red stain. We also studied a representative subset of veins for markers of monocyte/macrophage content, cell proliferation, apoptosis, and neoangiogenesis. Neointima occupied >20% of the lumen in 57% of fully circumferential vein samples, and neointimal hyperplasia associated positively with age and inversely with black race. The neointima was usually irregularly thickened, sometimes concentric, and contained α-smooth muscle actin-expressing cells of smooth muscle or myofibroblast origin. Proteoglycans admixed with lesser amounts of collagen constituted the predominant matrix in the neointima. In 82% of vein samples, the media of vessel walls contained large aggregates of collagen. A minority of veins expressed markers of inflammation, cell proliferation, cell death, calcification, or neoangiogenesis. In conclusion, we observed preexisting abnormalities, including neointimal hyperplasia and prominent accumulation of extracellular matrix, in veins used for AVF creation from a substantial proportion of this cohort.
The ACC forum on the future: delivering quality care in the 21st century2∗The recommendations set forth in this report are those of the Conference participants and do not necessarily reflect the official position of the American College of Cardiology.22Reprint requests and correspondence: American College of Cardiology, 9111 Old Georgetown Road, Bethesda, Maryland 20814. Attention: Educational Services Department (800-253-4636 ext. 694).
Authors: Ruth L Collins-Nakai, Leonard S Dreifus, Francis J Klocke, Richard P Lewis
Journal: Journal of the American College of Cardiology (2000)
Improved Survival of Older Patients with Mantle Cell Lymphoma (MCL) with Front-Line Cytarabine-Based Immunochemotherapy
Authors: Sumita Ratnasingam, Michael Gilbertson, Zoe McQuilten, Kay T Htun, George Grigoriadis, Swe Myo Htet, Philip Campbell, Khai Li Chai, Hang Quach, Sushrut S. Patil, Jake Shortt, Stephen Opat
Journal: Blood (2016)
Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience
Authors: Jonas Paludo, Nishanth Vallumsetla, Stephen Ansell, Abhisek Swaika, Tania Jain, Sikander Ailawadhi, Craig B. Reeder, Shaji Kumar, Thomas M. Habermann, Thomas E. Witzig, Ronald S. Go, Francis K Buadi, Wilson I Gonsalves, Angela Dispenzieri, Martha Q. Lacy, Carrie A Thompson, David Dingli, Suzanne R. Hayman, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz, Prashant Kapoor
Journal: Blood (2016)
Inclusion of Demographic-Specific Information in Studies Supporting US Food &amp; Drug Administration Approval of High-Risk Medical Devices
Authors: Sanket S. Dhruva, Carolyn M. Mazure, Joseph S. Ross, Rita F. Redberg
Journal: JAMA Internal Medicine (2017)

This analysis characterizes the studies used to support US Food & Drug Administration 2015 premarket approval of devices, particularly findings of device safety and effectiveness for women, the elderly, and minorities.
Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice
Authors: Zoe A. Klein, Hideyuki Takahashi, Mengxiao Ma, Massimiliano Stagi, Melissa Zhou, TuKiet T. Lam, Stephen M. Strittmatter
Journal: Neuron (2017)
Structure-Based Drug Design Targeting a Pro-Metastatic Collagen Lysyl Hydroxylase
Authors: H. Guo, C.-L. Tsai, Y. Chen, M. Terajima, M. Yamauchi, S. Alvarado, E.J. Cho, K. Dalby, G.N. Phillips, J.A. Tainer, J.M. Kurie
Journal: Journal of Thoracic Oncology (2017)
SR16388 inhibits non-small cell lung tumor growth and angiogenesis
Authors: Peter D. Hobbs, Wan-Ru Chao, Khalid Amin, Carol Green, Theresamai Le, Toufan Parman, Barbara Sato, Robert Swezey, Mary Tanga, Dawn Yean
Journal: Cancer Research (2006)

3820   We had previously determined that the steroidal antitumor agent, SR16388, inhibited matrix development and reduced microvessel density in a wound healing model, and further that the compound inhibited tumor growth and angiogenesis in a PC3 mouse xenograft model of human prostate cancer. In the present study we proposed to: (1) further characterize the effects of the drug on microvessel development; then (2) to determine if the tumor growth inhibitory activity of SR16388 extends to androgen receptor-positive but androgen-independent prostate cancer and to other invasive carcinomas, in particular non-small cell lung adenocarcinoma. Finally,oral bioavailability and pharmacokinetics would be determined in the rat and the dog. The effects of SR16388 and of a panel of closely related steroids on growth of human dermal microvascular endothelial cells (Clonetics) were compared. SR16388 was significantly more potent (IC50 = 80nM) than the analogs (IC50 = 0.6 - 10 μM). SR16388 (2 μM) prevented formation of tube-like structures in Matrigel after HMVECs were treated with the drug for 8h. In a modified Boyden chamber assay, SR16388 inhibited the migration of HMVECs through collagen membrane by 80% at 500 nM. SR16388 potently inhibited the growth (IC50 =100 and 120 nM) of both A549 non-small cell lung adenocarcinoma cells, and metastatic androgen receptor-positive, but androgen-independent, LNCaP C4-2B prostate cancer cells in culture. The transcription factor Stat3 (Signal Transducers and Activators of Transcription-3) was determined by Western blot to be tyrosine phosphorylated in A549 cells, and SR16388 significantly attenuated Stat3 phosphorylation. Stat3 activation may contribute to carcinogenesis by regulation of expression of several proangiogenic and antiapoptotic factors in human tumors. However, Stat3 was not constitutively phosphorylated in LNCaP C4-2B cells or in PC3 androgen-independent prostate cancer cells. SR16388 was evaluated using a xenograft nude mouse model for its in vivo antitumor activity against A549 tumors. In this study, SR16388 inhibited tumor growth in a dose- response manner at a single daily oral dose of 10, 30, and 100 mg/kg. A dose-response effect was observed for oral dosing of SR16388 in two mouse xenograft studies. This preliminary finding of the drugs efficacy by oral administration was confirmed on determination of favorable oral bioavailabilty and t1/2 of elimination in both male and female Sprague-Dawley rats and Beagle dogs. These data support the further development of orally administered SR16388 for the treatment of advanced neoplasms, including non-small cell lung cancers. Direct effects of the drug on microvascular endothelial cells contribute to its angiogenesis inhibitory activity. Inhibition of Stat3 activation may be a component of the effects of SR16388 on tumors that express constitutively activated Stat3.
Itraconazole, an Oral Antifungal Drug, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents
Authors: Juan J Gu, Lianjuan Yang, Cory Mavis, Matthew J. Barth, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2016)
Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients
Authors: Jie Sun, Hua Meng, Lu Yao, Meng Lv, Jian Bai, Jianguang Zhang, Lientu Wang, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie
Journal: Clinical Cancer Research (2017)

Purpose: The prevalence of mutations in cancer susceptibility genes such as BRCA1 and BRCA2 and other cancer susceptibility genes and their clinical relevance are largely unknown among a large series of unselected breast cancer patients in the Chinese population.Experimental Design: A total of 8,085 consecutive unselected Chinese breast cancer patients were enrolled. Germline mutations in 46 cancer susceptibility genes were detected using a 62-gene panel.Results: Pathogenic mutations were identified in 9.2% of patients among the 8,085 unselected breast cancer patients. Of these, 5.3% of patients carried a BRCA1 or BRCA2 mutation (1.8% in BRCA1 and 3.5% in BRCA2), 2.9% carried other breast cancer susceptibility genes (BOCG) and 1.0% carried another cancer susceptibility genes. Triple-negative breast cancers had the highest prevalence of BRCA1/2 mutations (11.2%) and other BOCG mutations (3.8%) among the four molecular subgroups, whereas ER-/PR-HER2+ breast cancers had the lowest mutations in BRCA1/2 (1.8%) and BOCG (1.6%). In addition, BRCA1 mutation carriers had a significant worse disease-free survival [unadjusted hazard ratio (HR) 1.60; 95% confidence interval (CI) 1.10-2.34; P = 0.014] and disease-specific survival (unadjusted HR 1.96; 95% CI, 1.03-3.65; P = 0.040) than did non-carriers, whereas no significant difference in survival was found between BRCA2 mutation carriers and non-carriers.Conclusions: 9.2% of breast cancer patients carry a pathogenic mutation in cancer susceptibility genes in this large unselected series. Triple-negative breast cancers have the highest prevalence of mutations in BRCA1 /2 and other breast cancer susceptibility genes among the four molecular subgroups, whereas ER-/PR-HER2+ breast cancers had the lowest mutations in these genes. Clin Cancer Res; 23(20); 6113-9. ©2017 AACR.
Racial disparity in Hodgkin lymphoma response to initial treatment in the inner city population.
Authors: Surabhi Pathak, Ankit Mangla, Romy Thekkekara, Shweta Gupta
Journal: Journal of Clinical Oncology (2014)

e19556 Background: Hodgkin lymphoma (HL) is one of the most curable malignancies. Studies have shown that lower socioeconomic status (SES) and minority patients may have worse outcomes compared to whites and higher SES patients. PET-scan has been utilized in initial staging, assessment of response to therapy, evaluation of residual disease and detecting relapse in patients with HL. We undertook this study to assess response to initial therapy in patients with newly diagnosed HL from different ethnicities at our hospital. Methods: John H Stroger Jr. Hospital of Cook County is an inner city safety net public hospital in Chicago. We identified all patients with diagnosis of HL from Jan 2006 to Dec 2012 from our hospital tumor registry. All charts were retrospectively reviewed for presence of pre and post treatment PET-scans, stage, age, sex, ethnicity, laboratory parameters at diagnosis (blood counts, albumin, LDH, sedimentation rate), presence of bulky disease and treatment. Patient charts with incomplete data and no PET scans were excluded. Patients were divided in ethnic groups. African American (AA) and hispanic (HSP) patients were studied in detail including complete remission (CR) as defined by negative post treatment PET scan. Fishers exact test and Kaplan Meier analysis were used for statistical analysis. Results: A total of 113 charts were screened and 47 met inclusion criteria. There were 19 AA, 15 HSP, 10 Caucasian (WH) and 3 Asian patients. Comparing AA and HSP, AA were more likely to have stage IIB-IV (63% vs 53%, p=NS), anemia (50% vs 0%, p=0.001), leucocytosis (17% vs 0%, p=NS), low albumin (67% vs 27%, p=0.03), M:F ratio of 5:1 vs 2:1, older average age 34.2 vs 25.6 years (p=0.006). Despite this, HSP had a worse CR rate of 53% compared to 95% for AA (p=0.01) and 90% for WH. Overall survival was not significantly worse for HSP compared to AA (p=0.39). Conclusions: HSP patients with newly diagnosed HL have inferior response to initial therapy despite having lower stage, less lab abnormalities and similar bulky disease compared to AA, suggesting a possible role of personal pharmacogenomics or yet unsuspected adverse prognostic factors for this ethnic group. This subset needs to be studied more closely in prospective studies.
A new intraductal radiofrequency ablation device for inoperable biliopancreatic tumors complicated by obstructive jaundice: the IGNITE-1 study
Authors: Wim Laleman, Schalk van der Merwe, Len Verbeke, Dirk Vanbeckevoort, Raymond Aerts, Hans Prenen, Eric Van Cutsem, Chris Verslype
Journal: Endoscopy (2017)

Abstract Background and study aims Biliary stenting of unresectable malignant bile duct obstruction is generally accepted as the standard of care but it can be hampered by tumor ingrowth and stent dysfunction. We aimed to test the feasibility, safety, and biliary patency rate of a new endoscopically applied intraductal radiofrequency ablation (RFA) device. Patients and methods Eighteen patients with inoperable malignant biliary obstruction underwent endoscopic retrograde cholangiopancreatography (ERCP)-directed RFA and stenting. Results Between December 2014 and November 2015, 18 patients underwent RFA to the intended region, with no complications within 3 months of the procedure. Bilirubin levels post-RFA and stenting decreased significantly (7.8 ± 1 mg/dL to 1.7 ± 0.4 mg/dL; P &lt; 0.001). At 90 and 180 days post-intervention, biliary patency was maintained in 80 % and 69 % of patients still alive at that time, respectively. The median overall stent patency was 110 days (range 16 – 374), with a median patient survival of 227 days (range 16 – 374). Conclusion Intraductal RFA using a new device in patients with inoperable biliopancreatic cancer complicated by jaundice appeared feasible and safe with acceptable biliary patency. Randomized trials with prolonged follow-up are warranted. ClinTrials.gov: NCT02468076.
Suicidal Behaviors Within Army Units
Authors: Charles W. Hoge, Christopher G. Ivany, Amy B. Adler
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.
Authors: Mark H. O'Hara, Thomas Benjamin Karasic, Irina Vasilevskaya, Maryann Redlinger, Arturo Loaiza-Bonilla, Ursina R. Teitelbaum, Bruce J. Giantonio, Nevena Damjanov, Kim Anna Reiss, Mark Alan Rosen, Daniel F Heitjan, Andrea B. Troxel, Ravi K. Amaravadi, Peter J. O'Dwyer
Journal: Journal of Clinical Oncology (2017)

3545 Background: Colorectal cancer (CRC) cells can become resistant to chemotherapy and anti-angiogenic therapy through autophagy. The antimalarial agent hydroxychloroquine (HCQ) is a potent inhibitor of autophagy, and in vivo studies in CRC cell models show significant decrease tumor volume when these autophagy inhibitors were combined with oxaliplatin and bevacizumab. We previously reported safety with HCQ 600mg BID in combination with standard front-line FOLFOX and bevacizumab in a Phase I study in metastatic CRC patients. We report the results of a single-arm phase II trial of patients with previously untreated stage IV CRC with good performance status and adequate hematologic and biochemical indices. Methods: Patients were treated with standard doses of mFOLFOX6 and bevacizumab with HCQ 600mg BID. Imaging was obtained every 2 months. Results: 37 patients were enrolled, 62% male, 89% Caucasian, median age 61, 65% ECOG PS 0, and 73% colon primary. Twenty-eight patients were evaluable for response as 2 patients did not start therapy and 7 patients withdrew prior to first response assessment. The ORR was 68% with an 11% CR rate. The median time to response was 3.1 months. Responses were independent of genomic aberrations within tumor tissue, specifically KRAS, TP53, BRAF, and PIK3CA. Median PFS and duration of response were not interpretable given that only 25% of patients came off trial for progression; all other patients withdrew to pursue surgery or liver embolization therapy, to receive therapy elsewhere, or due to toxicity associated with chemotherapy. The 1 year OS rate was 74%, and median OS has not been reached. The most common G3 or higher adverse events included neutropenia (31%), fatigue (11%), thromboembolism (9%), and cardiac events (9%). HCQ-attributable side effects included G1-3 insomnia (26%), G1-3 anxiety (20%), G1 visual disturbances (11%) and G3 allergy (3%). The majority of patients had increase in both LC3 and p62 in peripheral blood mononuclear cells and exhibited an increase in autophagosomes within the cytosol by electron microscopy. Conclusions: These data are promising and further evaluation in a randomized controlled trial is planned. Clinical trial information: NCT01206530.
HEAD IMPACT CHARACTERISTICS IN YOUTH ICE HOCKEY
Authors: Declan Patton, Krolikowski Maciek, Emery Carolyn
Journal: British Journal of Sports Medicine (2017)

Background Few studies have investigated head impacts in youth ice hockey, none of which have reported impact mechanisms. Objective To investigate head impact characteristics in youth ice hockey. Design Video analysis. Setting 2013/2014 Calgary bantam (13–14 years) ice hockey season. Methods A previously compiled video database of 7260 bantam ice hockey player-to-player contacts from 22 games was searched for head impact cases. Eight games were randomly selected, two elite and six non-elite, from which head impact cases were analysed. Results A total of 254 head impact cases were identified, which represented 3.5% of all player-to-player contacts at a rate of 11.5 head contacts per game. A total of 100 head impact cases were analysed. Two-thirds of all cases (67%) occurred in close proximity to the boards and 11% of all cases resulted in a penalty. Over half of all impacts (55%) were to the side of the helmet, followed by the cage (29%), rear (7%), front (6%) and top (2%). The primary impacting object was an opposing player in 69% of all cases with the most common being the shoulder (31%), helmet (12%) and glove (10%). The impacting object was the glass and boards for 17% and 11% of all cases, respectively. A secondary impact occurred in 21% of all cases, which was most commonly to the side of the helmet and impacting the glass. One case involving a tertiary impact was identified, which comprised of two impacts to the shoulder of an opposing player and then an impact against the boards during the subsequent fall. Conclusions Impacts in youth ice hockey games are typically to the side and cage of helmets by an opposing player. Helmet performance and standards testing should include representative impacts by compliant surfaces to simulate player-to-player contact.
B7-H4 enhances the differentiation of murine leukemia-initiating cells via the PTEN/AKT/RCOR2/RUNX1 pathways
Authors: F Xia, Y Zhang, L Xie, H Jiang, H Zeng, C Chen, L Liu, X He, X Hao, X Fang, X Liu, F Zhang, H Gu, J Wan, Y Cheng, C C Zhang, G-Q Chen, Y Lu, Z Yu, J Zheng
Journal: Leukemia (2017)

der(1;7)(q10;p10).We observed that MDS patients with der(1;7) (q10;p10) present male predominance and have a better outcome than the -7/del(7q) group (Supplementary Table 4).Our findings revealed that the mutation spectrum of patients with der(1;7)(q10; p10) was different from that of MDS with -7/del(7q).We demonstrate for the first time, to our knowledge, that der(1;7) (q10;p10) is associated with a high frequency of mutations in RUNX1.Further studies are needed to clarify whether and how mutations of RUNX1 contribute to the pathogenesis of this subtype.
Detection and monitoring of lung inflammation in cystic fibrosis during respiratory tract exacerbation using diffusion-weighted magnetic resonance imaging
Authors: Pierluigi Ciet, Silvia Bertolo, Mirco Ros, Eleni Rosalina Andrinopoulou, Valentina Tavano, Francesca Lucca, Thorsten Feiweier, Gabriel P. Krestin, Harm A.W.M. Tiddens, Giovanni Morana
Journal: European Respiratory Journal (2017)

The aim was to investigate whether diffusion-weighted magnetic resonance imaging (DWI) detects and monitors inflammatory and lung function changes during respiratory tract exacerbations (RTE) treatment in patients with cystic fibrosis (CF). 29 patients with RTE underwent DWI pre- and post-antibiotic treatment. A control group of 27 stable patients, matched for age and sex, underwent DWI with the same time gap as those undergoing RTE treatment. Clinical status and lung function were assessed at each DWI time point. The CF-MRI scoring system was used to assess structural lung changes in both CF groups. Significant reduction in the DWI score over the course of antibiotic treatment (p&lt;0.0001) was observed in patients with RTE, but not in the control group. DWI score had a strong inverse correlation with clinical status (r=−0.504, p&lt;0.0001) and lung function (r=−0.635, p&lt;0.0001) in patients with RTE. Interestingly, there were persistent significant differences in the CF-MRI score between the RTE and control group at both baseline and follow-up (p&lt;0.001), while the differences in DWI score were only observed at baseline (p&lt;0.001). DWI is a promising imaging method for noninvasive detection of pulmonary inflammation during RTE, and may be used to monitor treatment efficacy of anti-inflammatory treatment.
Gynaecologist at UK’s largest Polish speaking clinic is struck off
Authors: Clare Dyer
Journal: BMJ (2017)

A gynaecologist who worked in private practice at the UK’s largest Polish speaking clinic has been struck off for recklessness and dishonesty.

Krystyna Tajchman, who qualified in Poznan in 1980, faced charges relating to the treatment of two patients at the Green Surgery in Greenwich, southeast London. She did not attend her hearing at the Medical Practitioners Tribunal Service in Manchester.

Tajchman was found to have performed two procedures on “patient A” that were not clinically indicated: a cervical cauterisation in 2011 and a colposcopy in 2013. In neither case did she perform a proper examination. …